Given the sensitivity of MCC cells to IFNα, developing IFNα-equipped Fab–peptide–HLA-I fusion proteins equipped with MCPyV-derived epitopes may represent a promising new immunotherapy approach for MCPyV-associated MCC. Here, IFNA2 is linked to Merkel cell skin cancer.